STAT+: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial
SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.
The mid-stage results for orforglipron, published Friday in the New England Journal of Medicine and presented here at the American Diabetes Association conference, match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year.
By the end of trial, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period, the authors said.
Continue to STAT+ to read the full story…
